Clinical Trials
16 trialsNCT03486873 2026-06-05
MK-3475-587
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07007312 2026-06-03
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Kura Oncology, Inc.
Phase 3 Recruiting
NCT07504458 2026-04-16
QUATRO-APL
Quetzal Therapeutics
Phase 3 Recruiting
NCT02730299 2026-02-25
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
Gamida Cell ltd
Phase 3 Completed
NCT06652633 2026-02-05
Hesperia
Lakefront Biotherapeutics NV
Phase 3 Recruiting
NCT04260698 2025-07-02
Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Gamida Cell ltd
Phase 3 Completed
NCT06401356 2025-06-22
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Novartis
Phase 3 Recruiting
NCT01437787 2025-03-05
JAKARTA
Bristol-Myers Squibb
Phase 3 Completed
NCT05438498 2023-09-08
Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2
MediMergent, LLC
Phase 3 Terminated
NCT01345019 2022-11-08
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
Amgen
Phase 3 Completed
NCT02999854 2022-05-24
HATCY
Kiadis Pharma
Phase 3 Terminated
NCT00471497 2020-11-18
ENESTnd
Novartis
Phase 3 Completed
NCT01254630 2019-09-30
V212-011
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00790036 2017-07-12
PILLAR2
Novartis
Phase 3 Completed
NCT00519090 2011-11-07
ENEST
Novartis
Phase 3 Terminated
NCT00044759 2007-10-10
Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 3 Completed